NASDAQ:AKTX

Akari Therapeutics Stock Forecast, Price & News

$1.70
-0.02 (-1.16 %)
(As of 09/23/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.65
$1.75
50-Day Range
$1.59
$1.87
52-Week Range
$1.42
$4.21
Volume190,532 shs
Average Volume285,047 shs
Market Capitalization$80.91 million
P/E RatioN/A
Dividend YieldN/A
Beta1.21
30 days | 90 days | 365 days | Advanced Chart
Receive AKTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Akari Therapeutics logo

About Akari Therapeutics

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.27 out of 5 stars

Medical Sector

1138th out of 1,351 stocks

Pharmaceutical Preparations Industry

552nd out of 664 stocks

Analyst Opinion: 0.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Akari Therapeutics (NASDAQ:AKTX) Frequently Asked Questions

What stocks does MarketBeat like better than Akari Therapeutics?

Wall Street analysts have given Akari Therapeutics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Akari Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Akari Therapeutics?

Akari Therapeutics saw a drop in short interest in the month of August. As of August 13th, there was short interest totaling 40,500 shares, a drop of 17.8% from the July 29th total of 49,300 shares. Based on an average daily trading volume, of 152,900 shares, the days-to-cover ratio is currently 0.3 days.
View Akari Therapeutics' Short Interest
.

When is Akari Therapeutics' next earnings date?

Akari Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, December 10th 2021.
View our earnings forecast for Akari Therapeutics
.

How were Akari Therapeutics' earnings last quarter?

Akari Therapeutics, Plc (NASDAQ:AKTX) announced its earnings results on Tuesday, June, 29th. The biopharmaceutical company reported ($0.15) EPS for the quarter.
View Akari Therapeutics' earnings history
.

How has Akari Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Akari Therapeutics' stock was trading at $1.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AKTX shares have increased by 10.4% and is now trading at $1.70.
View which stocks have been most impacted by COVID-19
.

Who are Akari Therapeutics' key executives?

Akari Therapeutics' management team includes the following people:
  • Clive Stuart Richardson, CEO, Chief Operating Officer & Director
  • Torsten Hombeck, Chief Financial & Accounting Officer
  • Miles Nunn, Chief Scientific Officer
  • Wynne Weston-Davies, Medical Director

What other stocks do shareholders of Akari Therapeutics own?

What is Akari Therapeutics' stock symbol?

Akari Therapeutics trades on the NASDAQ under the ticker symbol "AKTX."

Who are Akari Therapeutics' major shareholders?

Akari Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Omnia Family Wealth LLC (0.98%), Renaissance Technologies LLC (0.32%), Citadel Advisors LLC (0.11%) and HighTower Advisors LLC (0.05%).
View institutional ownership trends for Akari Therapeutics
.

Which major investors are buying Akari Therapeutics stock?

AKTX stock was bought by a variety of institutional investors in the last quarter, including Omnia Family Wealth LLC, HighTower Advisors LLC, Citadel Advisors LLC, and Renaissance Technologies LLC.
View insider buying and selling activity for Akari Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Akari Therapeutics?

Shares of AKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Akari Therapeutics' stock price today?

One share of AKTX stock can currently be purchased for approximately $1.70.

How much money does Akari Therapeutics make?

Akari Therapeutics has a market capitalization of $80.91 million. The biopharmaceutical company earns $-17,080,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis.

How many employees does Akari Therapeutics have?

Akari Therapeutics employs 9 workers across the globe.

What is Akari Therapeutics' official website?

The official website for Akari Therapeutics is www.akaritx.com.

Where are Akari Therapeutics' headquarters?

Akari Therapeutics is headquartered at 75/76 WIMPOLE STREET, LONDON X0, W1G 9RT.

How can I contact Akari Therapeutics?

Akari Therapeutics' mailing address is 75/76 WIMPOLE STREET, LONDON X0, W1G 9RT. The biopharmaceutical company can be reached via phone at 442080040261 or via email at [email protected].


This page was last updated on 9/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.